Next Article in Journal
Treatment and Prognosis of Patients with Lung Cancer and Combined Interstitial Lung Disease
Next Article in Special Issue
Epigenetically Downregulated Breast Cancer Gene 2 through Acetyltransferase Lysine Acetyltransferase 2B Increases the Sensitivity of Colorectal Cancer to Olaparib
Previous Article in Journal
Anticancer Potential of the Cyclolinopeptides
Previous Article in Special Issue
Assessment of Colorectal Cancer Risk Factors through the Application of Network-Based Approaches in a Racially Diverse Cohort of Colon Organoid Stem Cells
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 15
Issue 15
10.3390/cancers15153875
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Endoscopic Treatment of T1 Colorectal Cancer

by
Klaus Metter
1,*,
Stephanie Ellen Weißinger
2,
Alinda Várnai-Händel
3,
Karl-Ernst Grund
4 and
Franz Ludwig Dumoulin
5
1
Klinik für Gastroenterologie, Hepatologie und Diabetologie, Alb Fils Kliniken, Klinik am Eichert, Eichertstraße 3, D-73035 Göppingen, Germany
2
Institut für Pathologie, Alb Fils Kliniken, Klinik am Eichert, Eichertstraße 3, D-73035 Göppingen, Germany
3
Institut für Pathologie Bonn Duisdorf, Heilsbachstr. 11, D-53125 Bonn, Germany
4
Experimentelle Chirurgische Endoskopie (CETEX), Universitätsklinikum Tübingen, Waldhörnlestraße 22, D-72072 Tübingen, Germany
5
Innere Medizin/Gastroenterologie, Gemeinschaftskrankenhaus Bonn, Prinz Albert Str. 40, D-53113 Bonn, Germany
*
Author to whom correspondence should be addressed.
Cancers 2023, 15(15), 3875; https://doi.org/10.3390/cancers15153875
Submission received: 12 June 2023 / Revised: 24 July 2023 / Accepted: 28 July 2023 / Published: 30 July 2023
(This article belongs to the Special Issue Colorectal Cancers: From Present Problems to Future Solutions Volume II)
Browse Figures
Review Reports Versions Notes

Abstract

:

Simple Summary

Endoscopic resection of early-stage colorectal cancer is sufficient if histopathology indicates a low risk for lymph-node metastasis. Among the factors associated with lymph-node metastasis, tumor infiltration depth into the submucosal layer seems to carry the lowest risk, particularly in the absence of other risk factors. Unfortunately, with current resection techniques, the quantity and quality of the submucosal layer are often insufficient. Thus, histopathology may become unreliable, and unnecessary surgery may result. A resection strategy using novel devices designed for endoscopic resection of a maximum quantity and quality of the submucosal layer should provide an advantage.

Abstract

Commonly accepted criteria for curative resection of T1 colorectal cancer include R0 resection with horizontal and vertical clear margins (R0), absence of lympho-vascular or vessel infiltration (L0, V0), a low to moderate histological grading (G1/2), low tumor cell budding, and limited (<1000 µm) infiltration into the submucosa. However, submucosal infiltration depth in the absence of other high-risk features has recently been questioned as a high-risk situation for lymph-node metastasis. Consequently, endoscopic resection techniques should focus on the acquisition of qualitatively and quantitively sufficient submucosal tissue. Here, we summarize the current literature on lymph-node metastasis risk after endoscopic resection of T1 colorectal cancer. Moreover, we discuss different endoscopic resection techniques with respect to the quality of the resected specimen.

1. Introduction

Colorectal cancer (CRC) is one of the most frequent malignancies in Western societies [1]. It most commonly evolves from benign precursor lesions (adenomas) over a long time period. This window of opportunity calls for preventive measures and various screening strategies ranging from fecal occult blood tests to scheduled endoscopic screening have been implemented. Recently, colonoscopy screening has been evaluated in a prospective randomized study and was shown to reduce mortality by 50% in the per protocol analysis [2]. Screening colonoscopy not only allows identification and removal of precursor lesions (i.e., adenomas) but it also detects an increasing number of early cancers—some of them diagnosed only after endoscopic removal as ‘polyp cancers’ [3].

2. Endoscopic Evaluation of Colorectal Lesions—Not Always Perfect

Endoscopic resection of T1 CRC is accepted as an oncological sufficient treatment if histopathology confirms a low lymph-node metastasis risk. Current guidelines recommend a thorough evaluation of all colorectal lesions before endoscopic resection to choose the appropriate resection technique in case of suspicious lesions [4]. High-definition endoscopy in combination with (virtual or dye) chromoendoscopy is recommended to evaluate surface and vessel structure and to predict the presence of submucosal infiltration in flat or sessile colorectal lesions prior to endoscopic resection, e.g., using the NICE (narrow band imaging international colorectal endoscopic) or JNET (Japanese NBI expert) classification [5,6]. In larger rectal lesions, additional imaging, particularly endoscopic ultrasound, may be considered [7]. In addition to surface and vessel pattern the size, morphology and localization of the lesion are important. In a large meta-analysis of over 5000 adenomas, the risk for submucosal invasive cancer increased from 9.2% for lesion sizes between 20 and 30 mm to 16.5% for lesions larger than 30 mm [8]. The risk for submucosal invasive cancer also varied greatly with the morphology and was lowest for lateral spreading tumors (LST) of granular homogeneous type and highest for LST nongranular type with pseudo-depression. There also was a higher risk for cancer in distal versus proximal localized lesions. The meticulous evaluation of a colorectal lesion is important to choose the correct resection strategy. It should minimize cases of unnecessary surgery as a consequence of a poor resection technique (resulting in a specimen that is inappropriate for accurate histopathology) and should also prevent potentially harmful attempts to resect lesions endoscopically that are not suitable for local treatment [9].
Endoscopic diagnosis, however, even with the use of magnifying endoscopy or the assistance of artificial intelligence systems, is far from perfect [10,11,12,13]. In a systematic review and meta-analysis, the sensitivity/specificity of virtual chromoendoscopy were 85%/94% for the diagnosis of submucosal invasive cancer and 77%/98% for the diagnosis of deep submucosal invasion [14]. Endoscopic optical diagnosis aims at the diagnosis of submucosal invasive cancer and quantifying the depth of submucosal invasion to choose the appropriate resection technique [15]. However, depth of submucosal invasion may not be a good predictor of lymph-node metastasis in the lower gastrointestinal tract [16]. Moreover, in daily routine, some cancers are not suspected at the time of polypectomy but diagnosed only afterward on histopathology. Given this diagnostic uncertainty, an ideal endoscopic resection technique, particularly for rectal lesions >20 mm that have a higher risk for initial submucosal invasive cancer than lesions in the proximal colon, should obtain a one-piece specimen with well-defined lateral margins and the highest possible quality and quantity of submucosal tissue. The specimen resected by such a technique would allow the optimal evaluation of resection margins even in cases of unexpected submucosal invasive cancer and, thus, maximize the chance of a curative endoscopic resection. In addition, such a resection technique should come with a low rate of complications, particularly a low perforation rate, to avoid potential tumor cell spread [7,17].

3. T1 CRC—Not All Criteria for ‘Curative’ vs. ‘Noncurative’ Resection Are Equally Important

In the case of endoscopic resection of T1 CRC, the final diagnosis of ‘curative’ (i.e., low lymph-node metastasis risk) versus ‘noncurative’ resection will depend on histological analysis of the resected specimen. Commonly accepted criteria for ‘curative’ endoscopic resection include (i) a complete resection (ideally as one-piece/en bloc resection) with horizontal and vertical margins free of tumor infiltration (R0), (ii) the absence of lymphatic or blood vessel infiltration (L0, V0), (iii) a low to moderate histological grading (G1/2), and (iv) a limited (<1000 µm) tumor infiltration depth into the submucosa [7,18,19,20]. In addition, high-grade tumor budding (defined as single cells or cell clusters at the tumor invasion front) has been established as an important independent predictor of lymph-node metastasis [21,22]. Other factors such as tumor localization in the sigmoid/rectum were found to be associated with a higher lymph-node metastasis risk [23,24,25] but conflicting results have also been reported [26]. The concept of endoscopic resection of T1CRC was confirmed in a recent meta-analysis of 71 studies including more than 5000 patients. The pooled cumulative incidence of recurrence was 3.3% (local recurrence 1.9%; metastatic disease 1.6%) with different recurrence rates for low- versus high-risk lesions (0.7% versus 7%). CRC-related mortality was high (41%) in patients with recurrence [27].
Not all of the abovementioned factors defining a ‘noncurative’ resection are equally important. In most studies, lympho-vascular invasion (L1), poor grading, and a high tumor cell budding were strongly associated with lymph-node metastasis. In contrast, submucosal infiltration depth > 1000 µm in the absence of all other high-risk features is probably associated with a relatively low risk of lymph-node metastasis. This was shown in a recent meta-analysis on 67 studies with 21.238 T1CRC patients with an overall lymph-node metastasis rate of 11%. When weighting the different predictive factors, only poor differentiation, a high tumor budding count, and lymph vessel infiltration were significant predictors of lymph-node metastasis. In eight of the included studies comprising a total of 1146 patients, submucosal invasion depth > 1000 µm was the only risk factor, and, in this constellation, the lymph-node metastasis rate was only 2.6% [16]. This finding is supported by more recent studies not included in the meta-analysis (Table 1).

4. Optimizing the Prediction of Lymph-Node Metastasis Risk of T1 CRC

As pointed out, only 11–15% of the patients who undergo surgical resections after an endoscopic ‘noncurative resection’ will actually be diagnosed with lymph-node metastasis [16,28,33]. Different approaches have been undertaken to meet the need for a more accurate prediction of the lymph-node metastasis risk after ‘noncurative’ endoscopic resections (Table 2). Kajiwara et al. analyzed 4673 T1 CRC patients (352 with lymph-node metastasis) and elaborated a nomogram from a multivariate model of a development cohort (n = 3080/4673) to predict lymph-node metastasis. Six independent risk factors were identified: female gender, distal tumor location, high tumor grading, lymph vessel infiltration, high tumor cell budding, and submucosal invasion depth > 1000 µm. The nomogram was subsequently used to calculate the lymph-node metastasis risk in the validation cohort (the remaining 1593 patients) and performed far better than the current Japanese and US guidelines [34]. Another large study used data from 3134 patients (10.2% with lymph-node metastasis) as an input for a machine learning system to predict lymph-node metastasis risk [35]. A neuronal network was trained with available clinical data (age, sex, tumor size, location, morphology, lymphatic and vascular invasion, and histologic grade) and validated on a different set of 939 patients. The area under the curve (AUC) for the prediction of lymph-node metastasis of the artificial intelligence system was significantly better than that of current guidelines (AUC 0.83 versus 0.73, p < 0.01). This finding could also be reproduced if the analysis was restricted to 517 cases with initial endoscopic resection (AUC 0.84 versus 0.77, p = 0.05). Lastly, tissue-based transcriptomic biomarkers and different messenger RNAs were used to predict lymph-node metastasis risk [36]. This study analyzed 330 specimens from patients with high-risk T1 CRC (29 with lymph-node metastasis). A transcriptomic panel consisting of four different micro RNAs and five messenger RNAs was applied to 46 serum samples for training and to an additional 142 serum and matching tissue samples for validation. A risk-stratification model which combined the results of the transcriptomic panel and clinical risk factors identified patients with lymph-node metastasis with high precision and limited potential surgical overtreatment to only 18% of all patients included in the study. By and large, these studies confirm the notion that submucosal infiltration depth per se is a weak risk factor for lymph-node metastasis.

5. Endoscopic Resection Techniques and Specimen Quality

The quality of a resected specimen is the key to correct histopathology. In particular, a complete resection submucosal layer is desired in cases of submucosal invasion, which, as pointed out above, is probably not an independent risk factor for lymph-node metastasis. The consequences of the quality of a specimen (piecemeal versus one-piece) for subsequent histopathology are shown in Figure 1. In this example, fragmentation and thermic artefacts prevent a reliable evaluation of submucosal infiltration depth and vertical resection margin [45].

5.1. ESD

While en bloc resection of smaller well lifting lesions can be achieved by EMR, current ESGE guidelines recommend ESD for resection of larger (than 2 cm) colorectal, but particularly rectal, lesions with suspicion of limited submucosal invasion [7]. ESD will reliably achieve a one-piece resection and allows for optimal control of the resection margins. In addition, very good results have been published for the resection of superficially invasive T1CRC [46,47]. ESD may, however, have a problem with the vertical resection margin in cases of deep submucosal invasion. Thus, a recent Western retrospective multicenter study with 207 colorectal ESDs reported a positive vertical margin in 57% of the cases, and a positive vertical margin was the most frequent reason for a ‘noncurative’ endoscopic resection [48]. A possible caveat regarding the vertical resection margin also comes from a small pilot study comparing colorectal specimens obtained by EMR (n = 6 benign lesions) versus ESD (n = 6, with one case of submucosal invasive cancer) and quite unexpectedly showed a better preserved and thicker submucosal layer in EMR specimens [49,50]. More reassuring are retrospective data from a multicenter study on 126 ESDs performed for lesions suspicious for focal deep submucosal invasion. In this report, en bloc and R0 rates were 96% and 77%, respectively. Moreover, 26% of the resections were curative, 30% showed submucosal invasion depth > 1000 µm with no other high-risk features, and only 17% were clearly noncurative due to lymph vessel infiltration or high budding [51].

5.2. Endoscopic Intermuscular Dissection (EID)

An attempt to optimize the vertical resection margin in the rectum is a recently described technique of EID. This technique dissects the lesions between the outer longitudinal and the inner circular muscle layer. The specimen will, thus, include the complete submucosal layer and allow an optimal histological assessment in cases of submucosal invasive cancer. In a recent prospective cohort study, 67 patients with suspected deeply invasive rectal cancer were treated. The technical success rate for a median lesion size of 25 mm was 96%. EID allowed a high R0 resection rate even for deeply invasive T1 rectal cancers (36/40 cases; 90%) and avoided rectal surgery in nearly half of the patients [52].

5.3. Endoscopic Full Thickness Resection (EFTR)

An EFTR would provide an optimal specimen for evaluation of submucosal infiltration depth and vertical margin. The most commonly used tool is the full thickness resection (FTRD) device. Its use is attractive, since the learning curve is relatively short. Moreover, procedure time and perforation rate for non-lifting lesions might be favorable. However, the FTRD device has a limitation for the size of the resected specimen, and its use is restricted to smaller lesions up to 15–20 mm [53,54]. For 92 non-lifting cancerous lesions, the reported R0 rate from the German FTRD study group was 60.9% when FTRD was used as the primary resection method and 87.5% when the method was applied after incomplete resection of a malignant lesion [55]. Data from the Netherlands on 132 primary resections of T1 CRC showed a curative resection rate of 60.8% after excluding deep submucosal invasion as risk factor [56].

5.4. Endoscopic Submucosal Resection (ESR)

ESR is carried out with specific devices designed to increase quality and quantity of resected submucosal layer with a minimal perforation risk [57,58]. FARIn U is a needle knife attached to an insulated glider for mucosal incision. The flat adenoma resection instrument (FARIn) is a partially insulated snare with a distal ceramic tip for submucosal resection. Similar to hybrid EMR/ESD, ESR consists of a complete mucosal incision followed by submucosal resection, for which the FARIn device is placed around the lesion and firmly pushed against the bowel wall during the resection [57,59]. A multicenter study on 93 lesions in various localizations (11 stomach, 25 colon, and 57 rectum) with a median size of 29 mm (range 10–70) showed technical feasibility in all cases. The en bloc and R0 resection rates were 70% and 63%, respectively, with a promising safety profile (two delayed bleedings, one micro-perforation, no need for emergency surgery, and no 30 day mortality); all R1 resections had a positive lateral, not vertical margin [57]. Initial data show more abundant submucosal tissue for ESR than for EMR specimens which is of particular importance in cases of submucosal invasive cancer (Figure 2a–c). A prospective study formally comparing precut EMR and ESR is underway.

6. Conclusions

Endoscopic resection of T1 CRC is accepted as adequate oncological treatment if lymph-node metastasis risk of the resected lesion is low. This is commonly accepted for horizontal and vertical margins free of tumor infiltration, absence of lymphatic or blood vessel infiltration (L0, V0), low to moderate histological grading (G1/2), low tumor cell budding, and a limited (<1000 µm) submucosal tumor infiltration depth. The histological assessment of these features will critically depend on the quality of the resected specimen, which itself depends on the endoscopic resection technique. Since submucosal infiltration depth > 1000 µm in the absence of all other high-risk features is probably associated with a relatively low risk of lymph-node metastasis, a good-quality specimen should include abundant submucosal tissue and minimal thermal artefacts, particularly at the vertical margin. The various resection methods currently available all have their specific benefits and limits; EFTR and EID will provide a full submucosal layer, but EFTR has size limits, and EID is limited to rectal lesions. ESD has no size limits and provides optimal control of lateral margins; it may, however, have limitations with vertical resection margins. ESR will resect close to the proper muscle layer, but it also has a size limit of 40 mm.

Author Contributions

Conceptualization, K.M., K.-E.G. and F.L.D.; figures, S.E.W. and A.V.-H. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

Dedication

This paper is dedicated to the commemoration of Dipl.-Ing. Günter Farin (deceased), the ingenious pioneer of electrosurgery for flexible endocopic therapy.

References

  1. Ferlay, J.; Colombet, M.; Soerjomataram, I.; Dyba, T.; Randi, G.; Bettio, M.; Gavin, A.; Visser, O.; Bray, F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer 2018, 103, 356–387. [Google Scholar] [CrossRef] [PubMed]
  2. Bretthauer, M.; Loberg, M.; Kaminski, M.F. Colonoscopy Screening and Colorectal Cancer Incidence and Mortality. Reply. N. Engl. J. Med. 2023, 388, 378–379. [Google Scholar] [CrossRef]
  3. Pox, C.P.; Schmiegel, W. [German S3-guideline colorectal carcinoma]. Dtsch. Med. Wochenschr. 2013, 138, 2545. [Google Scholar] [CrossRef]
  4. Bisschops, R.; East, J.E.; Hassan, C.; Hazewinkel, Y.; Kamiński, M.F.; Neumann, H.; Pellisé, M.; Antonelli, G.; Bustamante Balen, M.; Coron, E.; et al. Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline—Update 2019. Endoscopy 2019, 51, 1155–1179. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Hayashi, N.; Tanaka, S.; Hewett, D.G.; Kaltenbach, T.R.; Sano, Y.; Ponchon, T.; Saunders, B.P.; Rex, D.K.; Soetikno, R.M. Endoscopic prediction of deep submucosal invasive carcinoma: Validation of the narrow-band imaging international colorectal endoscopic (NICE) classification. Gastrointest Endosc. 2013, 78, 625–632. [Google Scholar] [CrossRef] [PubMed]
  6. Sano, Y.; Tanaka, S.; Kudo, S.E.; Saito, S.; Matsuda, T.; Wada, Y.; Fujii, T.; Ikematsu, H.; Uraoka, T.; Kobayashi, N.; et al. Narrow-band imaging (NBI) magnifying endoscopic classification of colorectal tumors proposed by the Japan NBI Expert Team. Dig. Endosc. 2016, 28, 526–533. [Google Scholar] [CrossRef] [PubMed]
  7. Pimentel-Nunes, P.; Libanio, D.; Bastiaansen, B.A.J.; Bhandari, P.; Bisschops, R.; Bourke, M.J.; Esposito, G.; Lemmers, A.; Maselli, R.; Messmann, H.; et al. Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline—Update 2022. Endoscopy 2022, 54, 591–622. [Google Scholar] [CrossRef]
  8. Bogie, R.M.M.; Veldman, M.H.J.; Snijders, L.; Winkens, B.; Kaltenbach, T.; Masclee, A.A.M.; Matsuda, T.; Rondagh, E.J.A.; Soetikno, R.; Tanaka, S.; et al. Endoscopic subtypes of colorectal laterally spreading tumors (LSTs) and the risk of submucosal invasion: A meta-analysis. Endoscopy 2018, 50, 263–282. [Google Scholar] [CrossRef]
  9. Pimentel-Nunes, P.; Dinis-Ribeiro, M.; Ponchon, T.; Repici, A.; Vieth, M.; De Ceglie, A.; Amato, A.; Berr, F.; Bhandari, P.; Bialek, A.; et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015, 47, 829–854. [Google Scholar] [CrossRef]
  10. Komeda, Y.; Kashida, H.; Sakurai, T.; Asakuma, Y.; Tribonias, G.; Nagai, T.; Kono, M.; Minaga, K.; Takenaka, M.; Arizumi, T.; et al. Magnifying Narrow Band Imaging (NBI) for the Diagnosis of Localized Colorectal Lesions Using the Japan NBI Expert Team (JNET) Classification. Oncology 2017, 93 (Suppl. S1), 49–54. [Google Scholar] [CrossRef]
  11. Endoscopic Classification Review, G. Update on the paris classification of superficial neoplastic lesions in the digestive tract. Endoscopy 2005, 37, 570–578. [Google Scholar] [CrossRef] [PubMed]
  12. Matsumura, T.; Ebigbo, A.; Rommele, C.; Ikematsu, H.; Ishigami, H.; Suzuki, T.; Harada, H.; Yada, T.; Takatori, Y.; Takeuchi, M.; et al. Diagnostic Value of Adding Magnifying Chromoendoscopy to Magnifying Narrow-Band Imaging Endoscopy for Colorectal Polyps. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 2023; in press. [Google Scholar] [CrossRef]
  13. Messmann, H.; Bisschops, R.; Antonelli, G.; Libanio, D.; Sinonquel, P.; Abdelrahim, M.; Ahmad, O.F.; Areia, M.; Bergman, J.; Bhandari, P.; et al. Expected value of artificial intelligence in gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2022, 54, 1211–1231. [Google Scholar] [CrossRef] [PubMed]
  14. Backes, Y.; Moss, A.; Reitsma, J.B.; Siersema, P.D.; Moons, L.M. Narrow Band Imaging, Magnifying Chromoendoscopy, and Gross Morphological Features for the Optical Diagnosis of T1 Colorectal Cancer and Deep Submucosal Invasion: A Systematic Review and Meta-Analysis. Am. J. Gastroenterol. 2017, 112, 54–64. [Google Scholar] [CrossRef] [PubMed]
  15. Shahidi, N.; Vosko, S.; van Hattem, W.A.; Sidhu, M.; Bourke, M.J. Optical evaluation: The crux for effective management of colorectal neoplasia. Therap. Adv. Gastroenterol. 2020, 13, 1756284820922746. [Google Scholar] [CrossRef] [PubMed]
  16. Zwager, L.W.; Bastiaansen, B.A.J.; Montazeri, N.S.M.; Hompes, R.; Barresi, V.; Ichimasa, K.; Kawachi, H.; Machado, I.; Masaki, T.; Sheng, W.; et al. Deep Submucosal Invasion Is Not an Independent Risk Factor for Lymph Node Metastasis in T1 Colorectal Cancer: A Meta-Analysis. Gastroenterology 2022, 163, 174–189. [Google Scholar] [CrossRef] [PubMed]
  17. Goto, S.; Hasegawa, S.; Hida, K.; Uozumi, R.; Kanemitsu, Y.; Watanabe, T.; Sugihara, K.; Sakai, Y.; Study Group for Nomogram of the Japanese Society for Cancer of the Colon and Rectum. Multicenter analysis of impact of anastomotic leakage on long-term oncologic outcomes after curative resection of colon cancer. Surgery 2017, 162, 317–324. [Google Scholar] [CrossRef]
  18. Tanaka, S.; Kashida, H.; Saito, Y.; Yahagi, N.; Yamano, H.; Saito, S.; Hisabe, T.; Yao, T.; Watanabe, M.; Yoshida, M.; et al. JGES guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection. Dig. Endosc. 2015, 27, 417–434. [Google Scholar] [CrossRef]
  19. Draganov, P.V.; Wang, A.Y.; Othman, M.O.; Fukami, N. AGA Institute Clinical Practice Update: Endoscopic Submucosal Dissection in the United States. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 2019, 17, 16–25.e11. [Google Scholar] [CrossRef] [Green Version]
  20. Vogel, J.D.; Felder, S.I.; Bhama, A.R.; Hawkins, A.T.; Langenfeld, S.J.; Shaffer, V.O.; Thorsen, A.J.; Weiser, M.R.; Chang, G.J.; Lightner, A.L.; et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer. Dis. Colon. Rectum. 2022, 65, 148–177. [Google Scholar] [CrossRef]
  21. Lugli, A.; Kirsch, R.; Ajioka, Y.; Bosman, F.; Cathomas, G.; Dawson, H.; El Zimaity, H.; Fléjou, J.F.; Hansen, T.P.; Hartmann, A.; et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod. Pathol. 2017, 30, 1299–1311. [Google Scholar] [CrossRef] [Green Version]
  22. Lugli, A.; Zlobec, I.; Berger, M.D.; Kirsch, R.; Nagtegaal, I.D. Tumour budding in solid cancers. Nat. Rev. Clin. Oncol. 2021, 18, 101–115. [Google Scholar] [CrossRef] [PubMed]
  23. Ichimasa, K.; Kudo, S.E.; Kouyama, Y.; Mochizuki, K.; Takashina, Y.; Misawa, M.; Mori, Y.; Hayashi, T.; Wakamura, K.; Miyachi, H. Tumor Location as a Prognostic Factor in T1 Colorectal Cancer. J. Anus. Rectum. Colon 2022, 6, 9–15. [Google Scholar] [CrossRef]
  24. Arthursson, V.; Medic, S.; Syk, I.; Rönnow, C.F.; Thorlacius, H. Risk of recurrence after endoscopic resection of nonpedunculated T1 colorectal cancer. Endoscopy 2022, 54, 1071–1077. [Google Scholar] [CrossRef]
  25. Mochizuki, K.; Kudo, S.E.; Ichimasa, K.; Kouyama, Y.; Matsudaira, S.; Takashina, Y.; Maeda, Y.; Ishigaki, T.; Nakamura, H.; Toyoshima, N.; et al. Left-sided location is a risk factor for lymph node metastasis of T1 colorectal cancer: A single-center retrospective study. Int. J. Colorectal Dis. 2020, 35, 1911–1919. [Google Scholar] [CrossRef] [PubMed]
  26. Zong, Z.; Li, H.; Hu, C.G.; Tang, F.X.; Liu, Z.Y.; Deng, P.; Zhou, T.C.; Yi, C.H. Predictors of lymph-node metastasis in surgically resected T1 colorectal cancer in Western populations. Gastroenterol. Rep. 2021, 9, 470–474. [Google Scholar] [CrossRef]
  27. Dang, H.; Dekkers, N.; le Cessie, S.; van Hooft, J.E.; van Leerdam, M.E.; Oldenburg, P.P.; Flothuis, L.; Schoones, J.W.; Langers, A.M.J.; Hardwick, J.C.H.; et al. Risk and Time Pattern of Recurrences After Local Endoscopic Resection of T1 Colorectal Cancer: A Meta-analysis. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 2022, 20, e298–e314. [Google Scholar] [CrossRef] [PubMed]
  28. Yasue, C.; Chino, A.; Takamatsu, M.; Namikawa, K.; Ide, D.; Saito, S.; Igarashi, M.; Fujisaki, J. Pathological risk factors and predictive endoscopic factors for lymph node metastasis of T1 colorectal cancer: A single-center study of 846 lesions. J. Gastroenterol. 2019, 54, 708–717. [Google Scholar] [CrossRef] [PubMed]
  29. Rönnow, C.F.; Arthursson, V.; Toth, E.; Krarup, P.M.; Syk, I.; Thorlacius, H. Lymphovascular Infiltration, Not Depth of Invasion, is the Critical Risk Factor of Metastases in Early Colorectal Cancer: Retrospective Population-based Cohort Study on Prospectively Collected Data, Including Validation. Ann. Surg. 2022, 275, e148–e154. [Google Scholar] [CrossRef]
  30. Yamaoka, Y.; Shiomi, A.; Kagawa, H.; Hino, H.; Manabe, S.; Chen, K.; Nanishi, K.; Notsu, A. Lymph node metastasis in T1 colorectal cancer with the only high-risk histology of submucosal invasion depth ≥ 1000 μm. Int. J. Colorectal Dis. 2022, 37, 2387–2395. [Google Scholar] [CrossRef]
  31. Morini, A.; Annicchiarico, A.; De Giorgi, F.; Ferioli, E.; Romboli, A.; Montali, F.; Crafa, P.; Costi, R. Local excision of T1 colorectal cancer: Good differentiation, absence of lymphovascular invasion, and limited tumor radial infiltration (≤4.25 mm) may allow avoiding radical surgery. Int. J. Colorectal Dis. 2022, 37, 2525–2533. [Google Scholar] [CrossRef]
  32. Santos-Antunes, J.; Pioche, M.; Ramos-Zabala, F.; Cecinato, P.; Gallego Rojo, F.J.; Barreiro, P.; Felix, C.; Sferrazza, S.; Berr, F.; Wagner, A.; et al. Risk of residual neoplasia after a noncurative colorectal endoscopic submucosal dissection for malignant lesions: A multinational study. Endoscopy 2023, 55, 235–244. [Google Scholar] [CrossRef]
  33. Kawachi, H.; Eishi, Y.; Ueno, H.; Nemoto, T.; Fujimori, T.; Iwashita, A.; Ajioka, Y.; Ochiai, A.; Ishiguro, S.; Shimoda, T.; et al. A three-tier classification system based on the depth of submucosal invasion and budding/sprouting can improve the treatment strategy for T1 colorectal cancer: A retrospective multicenter study. Mod. Pathol. 2015, 28, 872–879. [Google Scholar] [CrossRef] [Green Version]
  34. Kajiwara, Y.; Oka, S.; Tanaka, S.; Nakamura, T.; Saito, S.; Fukunaga, Y.; Takamatsu, M.; Kawachi, H.; Hotta, K.; Ikematsu, H.; et al. Nomogram as a novel predictive tool for lymph node metastasis in T1 colorectal cancer treated with endoscopic resection: A nationwide, multicenter study. Gastrointest Endosc. 2023, 97, 1119–1128.e5. [Google Scholar] [CrossRef]
  35. Kudo, S.E.; Ichimasa, K.; Villard, B.; Mori, Y.; Misawa, M.; Saito, S.; Hotta, K.; Saito, Y.; Matsuda, T.; Yamada, K.; et al. Artificial Intelligence System to Determine Risk of T1 Colorectal Cancer Metastasis to Lymph Node. Gastroenterology 2021, 160, 1075–1084.e1072. [Google Scholar] [CrossRef]
  36. Wada, Y.; Shimada, M.; Murano, T.; Takamaru, H.; Morine, Y.; Ikemoto, T.; Saito, Y.; Balaguer, F.; Bujanda, L.; Pellise, M.; et al. A Liquid Biopsy Assay for Noninvasive Identification of Lymph Node Metastases in T1 Colorectal Cancer. Gastroenterology 2021, 161, 151–162.e151. [Google Scholar] [CrossRef] [PubMed]
  37. Piao, Z.; Ge, R.; Wang, C. A proposal for grading the risk of lymph node metastasis after endoscopic resection of T1 colorectal cancer. Int. J. Colorectal Dis. 2023, 38, 25. [Google Scholar] [CrossRef]
  38. Miyazaki, K.; Wada, Y.; Okuno, K.; Murano, T.; Morine, Y.; Ikemoto, T.; Saito, Y.; Ikematsu, H.; Kinugasa, Y.; Shimada, M.; et al. An exosome-based liquid biopsy signature for pre-operative identification of lymph node metastasis in patients with pathological high-risk T1 colorectal cancer. Mol. Cancer 2023, 22, 2. [Google Scholar] [CrossRef] [PubMed]
  39. Takamatsu, M.; Yamamoto, N.; Kawachi, H.; Nakano, K.; Saito, S.; Fukunaga, Y.; Takeuchi, K. Prediction of lymph node metastasis in early colorectal cancer based on histologic images by artificial intelligence. Sci. Rep. 2022, 12, 2963. [Google Scholar] [CrossRef] [PubMed]
  40. Song, J.H.; Hong, Y.; Kim, E.R.; Kim, S.H.; Sohn, I. Utility of artificial intelligence with deep learning of hematoxylin and eosin-stained whole slide images to predict lymph node metastasis in T1 colorectal cancer using endoscopically resected specimens; prediction of lymph node metastasis in T1 colorectal cancer. J. Gastroenterol. 2022, 57, 654–666. [Google Scholar] [CrossRef]
  41. Kasahara, K.; Katsumata, K.; Saito, A.; Ishizaki, T.; Enomoto, M.; Mazaki, J.; Tago, T.; Nagakawa, Y.; Matsubayashi, J.; Nagao, T.; et al. Artificial intelligence predicts lymph node metastasis or risk of lymph node metastasis in T1 colorectal cancer. Int. J. Clin. Oncol. 2022, 27, 1570–1579. [Google Scholar] [CrossRef] [PubMed]
  42. Yan, S.; Ding, H.; Zhao, X.; Wang, J.; Deng, W. Development and validation of a nomogram for further decision of radical surgery in pT1 colorectal cancer after local resection. Int. J. Color. Dis. 2021, 36, 1499–1506. [Google Scholar] [CrossRef]
  43. Tang, M.; Wang, H.; Cao, Y.; Zeng, Z.; Shan, X.; Wang, L. Nomogram for predicting occurrence and prognosis of liver metastasis in colorectal cancer: A population-based study. Int. J. Color. Dis. 2021, 36, 271–282. [Google Scholar] [CrossRef]
  44. Kang, J.; Choi, Y.J.; Kim, I.K.; Lee, H.S.; Kim, H.; Baik, S.H.; Kim, N.K.; Lee, K.Y. LASSO-Based Machine Learning Algorithm for Prediction of Lymph Node Metastasis in T1 Colorectal Cancer. Cancer Res. Treat. Off. J. Korean Cancer Assoc. 2021, 53, 773–783. [Google Scholar] [CrossRef]
  45. Metter, K.; Dumoulin, F.L.; Grund, K.E.; Hildenbrand, R.; Varnai-Händel, A.D.; Weingardt-Kocher, S.; Weißinger, S.E. Endoskopische Submukosaresektion (ESR)- retrospektiver Kohortenvergleich von endoskopischen Resektaten mit/ohne vorherige Umschneidung. Z. Gastroenterol. 2022, 60, KA414. [Google Scholar] [CrossRef]
  46. Yamada, M.; Saito, Y.; Takamaru, H.; Sasaki, H.; Yokota, T.; Matsuyama, Y.; Sato, Y.; Sakamoto, T.; Nakajima, T.; Taniguchi, H.; et al. Long-term clinical outcomes of endoscopic submucosal dissection for colorectal neoplasms in 423 cases: A retrospective study. Endoscopy 2017, 49, 233–242. [Google Scholar] [CrossRef] [PubMed]
  47. Shin, J.; Kim, E.R.; Jang, H.J.; Baek, D.H.; Yang, D.H.; Lee, B.I.; Cho, K.B.; Cho, J.W.; Jung, S.A.; Hong, S.J.; et al. Long-term prognosis of curative endoscopic submucosal dissection for early colorectal cancer according to submucosal invasion: A multicenter cohort study. BMC Gastroenterol. 2022, 22, 417. [Google Scholar] [CrossRef] [PubMed]
  48. Spadaccini, M.; Bourke, M.J.; Maselli, R.; Pioche, M.; Bhandari, P.; Jacques, J.; Haji, A.; Yang, D.; Albeniz, E.; Kaminski, M.F.; et al. Clinical outcome of non-curative endoscopic submucosal dissection for early colorectal cancer. Gut 2022, 71, 1998–2004. [Google Scholar] [CrossRef]
  49. Clees, N.; Varnai-Handel, A.D.; Hildenbrand, R.; Grund, K.E.; Metter, K.; Dumoulin, F.L. Colorectal submucosa thickness in specimens obtained by EMR versus ESD: A retrospective pilot study. Endosc. Int. Open 2022, 10, E721–E726. [Google Scholar] [CrossRef]
  50. Ebigbo, A. Thickness of colorectal submucosal (SM) layer in resected specimens: Is more better? Endosc. Int. Open 2022, 10, E727–E728. [Google Scholar] [CrossRef]
  51. Patenotte, A.; Yzet, C.; Wallenhorst, T.; Subtil, F.; Leblanc, S.; Schaefer, M.; Walter, T.; Lambin, T.; Fenouil, T.; Lafeuille, P.; et al. Diagnostic endoscopic submucosal dissection for colorectal lesions with suspected deep invasion. Endoscopy 2023, 55, 192–197. [Google Scholar] [CrossRef] [PubMed]
  52. Moons, L.M.G.; Bastiaansen, B.A.J.; Richir, M.C.; Hazen, W.L.; Tuynman, J.; Elias, S.G.; Schrauwen, R.W.M.; Vleggaar, F.P.; Dekker, E.; Bos, P.; et al. Endoscopic intermuscular dissection for deep submucosal invasive cancer in the rectum: A new endoscopic approach. Endoscopy 2022, 54, 993–998. [Google Scholar] [CrossRef] [PubMed]
  53. Schmidt, A.; Beyna, T.; Schumacher, B.; Meining, A.; Richter-Schrag, H.J.; Messmann, H.; Neuhaus, H.; Albers, D.; Birk, M.; Thimme, R.; et al. Colonoscopic full-thickness resection using an over-the-scope device: A prospective multicentre study in various indications. Gut 2018, 67, 1280–1289. [Google Scholar] [CrossRef]
  54. Meier, B.; Stritzke, B.; Kuellmer, A.; Zervoulakos, P.; Huebner, G.H.; Repp, M.; Walter, B.; Meining, A.; Gutberlet, K.; Wiedbrauck, T.; et al. Efficacy and Safety of Endoscopic Full-Thickness Resection in the Colorectum: Results From the German Colonic FTRD Registry. Am. J. Gastroenterol. 2020, 115, 1998–2006. [Google Scholar] [CrossRef] [PubMed]
  55. Kuellmer, A.; Mueller, J.; Caca, K.; Aepli, P.; Albers, D.; Schumacher, B.; Glitsch, A.; Schafer, C.; Wallstabe, I.; Hofmann, C.; et al. Endoscopic full-thickness resection for early colorectal cancer. Gastrointest Endosc. 2019, 89, 1180–1189.e1181. [Google Scholar] [CrossRef]
  56. Zwager, L.W.; Bastiaansen, B.A.J.; van der Spek, B.W.; Heine, D.N.; Schreuder, R.M.; Perk, L.E.; Weusten, B.; Boonstra, J.J.; van der Sluis, H.; Wolters, H.J.; et al. Endoscopic full-thickness resection of T1 colorectal cancers: A retrospective analysis from a multicenter Dutch eFTR registry. Endoscopy 2022, 54, 475–485. [Google Scholar] [CrossRef]
  57. Metter, K.; Aepli, P.; Dumoulin, F.L.; Hayee, B.; Grund, K.E.; Farin, G.; Frei, R. Endoscopic submucosal resection: A technique using novel devices for incision and resection of neoplastic lesions. Endoscopy 2022, 54, 1001–1006. [Google Scholar] [CrossRef]
  58. Ebigbo, A. Endoscopic submucosal resection: A new addition to our toolbox? Endoscopy 2022, 54, 1007–1008. [Google Scholar] [CrossRef]
  59. Golder, S.K.; Schaller, T.; Farin, G.; Messmann, H.; Probst, A. Partially insulated cutting instruments for hybrid endoscopic submucosal dissection—The Flat Adenoma Resection Instruments (FARIn). Endoscopy 2016, 48 (Suppl. S1), E218–E219. [Google Scholar] [CrossRef]
Cancers 15 03875 g001 550
Figure 1. Examples of specimens from endoscopic resections. (a) Low-quality specimen: fragmented portions of a tubulo-villous adenoma with low-grade dysplasia. Due to the fragmentation, inking of the resection margins is not possible, the resection status cannot be assessed, and the submucosa cannot be measured. In addition, thermal artefacts are seen in the depth (asterisks) (hematoxylin and eosin stain). (b) High-quality specimen: one-piece resection of a tubulo-villous adenoma with serrated morphology and focal high-grade dysplasia. Inking can be performed both for the lateral (yellow) and the vertical (blue) resection margins. Thus, the resection status can be assessed, and the submucosal layer can be measured. Thermal artefacts are not seen. (hematoxylin and eosin stain). Images obtained using an Olympus BX41 microscope, Zeiss digital camera Axiocam105 color and a 2 × 0.06 Plan Neofluar objective (Zeiss Zen core 3.5 software). Image processing was performed with Microsoft PowerPoint, Version 2020.
Figure 1. Examples of specimens from endoscopic resections. (a) Low-quality specimen: fragmented portions of a tubulo-villous adenoma with low-grade dysplasia. Due to the fragmentation, inking of the resection margins is not possible, the resection status cannot be assessed, and the submucosa cannot be measured. In addition, thermal artefacts are seen in the depth (asterisks) (hematoxylin and eosin stain). (b) High-quality specimen: one-piece resection of a tubulo-villous adenoma with serrated morphology and focal high-grade dysplasia. Inking can be performed both for the lateral (yellow) and the vertical (blue) resection margins. Thus, the resection status can be assessed, and the submucosal layer can be measured. Thermal artefacts are not seen. (hematoxylin and eosin stain). Images obtained using an Olympus BX41 microscope, Zeiss digital camera Axiocam105 color and a 2 × 0.06 Plan Neofluar objective (Zeiss Zen core 3.5 software). Image processing was performed with Microsoft PowerPoint, Version 2020.
Cancers 15 03875 g001
Cancers 15 03875 g002 550
Figure 2. (a) EMR en bloc of a sessile serrated lesion with dysplasia with inked deep resection margin (black) (4× magnification, hematoxylin and eosin stain). Grid lines at 1000 µm intervals. Orthogonal to this, submucosa thickness is measured from the lamina muscularis mucosae to the deep vertical resection margin (black). (b) ESR en bloc of a tubulo-villous adenoma with serrated morphology and high-grade dysplasia and inked deep resection margin (blue), with measurement as above (hematoxylin and eosin stain). Note the differences in the thickness of the submucosal layer and the quality of the vertical margin in (a) (EMR) versus (b) (ESR). (c) Specimen obtained by ESR for a lesion with invasive carcinoma. En bloc specimen of a tubulo-villous adenoma with serrated morphology and focal high-grade dysplasia with transition into a well-differentiated invasive adenocarcinoma, intestinal type with infiltration of the submucosa. Tumor classification: pT1 (sm1) L0 V0 R0 G1. Inking of the deep resection margin was performed, and the distance of the lesion to the deep resection margin was measured (hematoxylin and eosin stain). Image acquisition and processing as given for Figure 1.
Figure 2. (a) EMR en bloc of a sessile serrated lesion with dysplasia with inked deep resection margin (black) (4× magnification, hematoxylin and eosin stain). Grid lines at 1000 µm intervals. Orthogonal to this, submucosa thickness is measured from the lamina muscularis mucosae to the deep vertical resection margin (black). (b) ESR en bloc of a tubulo-villous adenoma with serrated morphology and high-grade dysplasia and inked deep resection margin (blue), with measurement as above (hematoxylin and eosin stain). Note the differences in the thickness of the submucosal layer and the quality of the vertical margin in (a) (EMR) versus (b) (ESR). (c) Specimen obtained by ESR for a lesion with invasive carcinoma. En bloc specimen of a tubulo-villous adenoma with serrated morphology and focal high-grade dysplasia with transition into a well-differentiated invasive adenocarcinoma, intestinal type with infiltration of the submucosa. Tumor classification: pT1 (sm1) L0 V0 R0 G1. Inking of the deep resection margin was performed, and the distance of the lesion to the deep resection margin was measured (hematoxylin and eosin stain). Image acquisition and processing as given for Figure 1.
Cancers 15 03875 g002
Table
Table 1. Recent studies on lymph-node metastasis (LNM) in T1 CRC with deep submucosal invasion in the absence of other high-risk factors.
Table 1. Recent studies on lymph-node metastasis (LNM) in T1 CRC with deep submucosal invasion in the absence of other high-risk factors.
Study/YearPopulationLNM (per Total
Number of Cases)		LNM (sm Infiltration >1000 µm in Isolation)
Yasue et al., 2022 [28]Endoscopic, surgical74/864 (8.7%)1.6%
Rönnow et al., 2022 [29]Surgical150/1439 (10%)7.4%
Yamaoka et al., 2022 [30]Surgical70/519 (13.5%)3.8%
Morini et al., 2022 [31]Surgical15/122 (12.5%)2.9%
Santos-Antunes et al., 2023 [32]Endoscopic26/96 (27%)0.0%
Table
Table 2. Selected studies on prediction of lymph-node metastasis risk in T1 CRC.
Table 2. Selected studies on prediction of lymph-node metastasis risk in T1 CRC.
StudyMethod NumberResult
(Prediction LNM Risk)
Yasue et al. [28]HistologyN = 846LVI, budding and differentiation:
OR 8.09, 1.89, 2.09
Piao et al. [37]HistologyN = 271LVI and grading:
0.8% vs. 66.6% LNM
Miyazaki et al. [38]Exosomal miRNAs
from preoperative serum		N = 200AUC 0.84 for LNM
Kajiwara et al. [34]NomogramN = 4673SMI, budding, LVI, grading, location, sex
Takamatsu et al. [39]AI/deep learning
from H&E histology		N = 783 AUC 0.76 for LNM
Song et al. [40]AI/deep learning
from H&E histology		N = 400 AUC 0.76 for LNM
Kasahara et al. [41]AI/deep learning
from H&E histology		N = 146 Accuracy 81.8–86.3%
Yan et al. [42]NomogramN = 141LVI, location, grading
AUC 0.89
Wada et al. [36]Liquid biopsy
Micro RNA, mRNA		N = 330 AUC 0.90
Tang et al. [43]Multivariate analysisN = 476 Early-onset CRC with higher LNM rate
Kudo et al. [35]AI/deep learning
with various risk factors		N = 3134AUC 0.83 for cases with initial endoscopic resection (n = 517)
Kang et al. [44] Learning algorithm
with various factors		N = 316 AUC 0.76
Abbreviations: AI, artificial intelligence; AUC, area under the curve; CRC, colorectal cancer; H&E hematoxylin/eosin; LNM, lymph-node metastasis; LVI, lymphatic vessel infiltration; SMI, submucosal invasion depth.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Metter, K.; Weißinger, S.E.; Várnai-Händel, A.; Grund, K.-E.; Dumoulin, F.L. Endoscopic Treatment of T1 Colorectal Cancer. Cancers 2023, 15, 3875. https://doi.org/10.3390/cancers15153875

AMA Style

Metter K, Weißinger SE, Várnai-Händel A, Grund K-E, Dumoulin FL. Endoscopic Treatment of T1 Colorectal Cancer. Cancers. 2023; 15(15):3875. https://doi.org/10.3390/cancers15153875

Chicago/Turabian Style

Metter, Klaus, Stephanie Ellen Weißinger, Alinda Várnai-Händel, Karl-Ernst Grund, and Franz Ludwig Dumoulin. 2023. "Endoscopic Treatment of T1 Colorectal Cancer" Cancers 15, no. 15: 3875. https://doi.org/10.3390/cancers15153875

APA Style

Metter, K., Weißinger, S. E., Várnai-Händel, A., Grund, K. -E., & Dumoulin, F. L. (2023). Endoscopic Treatment of T1 Colorectal Cancer. Cancers, 15(15), 3875. https://doi.org/10.3390/cancers15153875

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop